Test Your Knowledge: Ten Questions about Multiple Sclerosis

This quiz is related to a Perspective in the February issue of *PLoS Medicine* (DOI: 10.1371/journal.pmed.0020033).

Gavin Yamey

**Question 1. Which is the most common form of multiple sclerosis (MS) at the onset of the disease?**
- Primary progressive
- Secondary progressive
- Relapsing, remitting

**Question 2. In Europe and North America, what is the approximate prevalence of MS?**
- One in 100
- One in 400
- One in 800
- One in 1,500

**Question 3. Which of the following is true about the epidemiology of MS?**
- There is a gradient of increasing prevalence with increasing latitude
- There is a gradient of increasing prevalence with decreasing latitude
- There is a gradient of increasing prevalence with increasing longitude
- There is a gradient of increasing prevalence with decreasing longitude

**Question 4. Based on clinical trial evidence, which of the following treatments is most effective for an acute relapse?**
- Corticosteroids
- Plasma exchange
- Interferon beta

**Question 5. Which of the following best reflects the evidence on using corticosteroids for treating an acute relapse of MS?**
- The optimal dose, duration of treatment, and route of administration are unclear
- There is good evidence that 15 days of treatment is more effective than five days
- There is good evidence that giving corticosteroids for an acute relapse can help prevent further relapses

**Question 6. Which of the following best reflects the evidence on interferon beta for treating MS?**
- There is good evidence that it prevents disease progression in people with secondary progressive MS
- There is no value in giving it after a first demyelinating event
- There is some evidence that interferon beta can reduce exacerbations and disease progression in people with relapsing, remitting disease

**Question 7. Which of the following treatments for fatigue in MS is well supported by high-quality evidence?**
- Exercise
- Behavior modification
- Pemoline
- None of the above

**Question 8. Which of the following best reflects our current knowledge of the relationship between stressful life events and acute exacerbations of MS?**
- A meta-analysis found a consistent association between stressful life events and subsequent exacerbations
- Although some individual studies have suggested an association between the two, a meta-analysis of all of these studies found no consistent association
- While some studies have suggested an association between the two, they were retrospective case-control studies, and the association has not been shown in a prospective study

---

**Citation:** Yamey G (2005) Test your knowledge: Ten questions about multiple sclerosis. *PLoS Med* 2(2): 51.

**Copyright:** © 2005 Gavin Yamey. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gavin Yamey is a senior editor at *PLoS Medicine*. E-mail: gyamey@plos.org

**DOI:** 10.1371/journal.pmed.0020051
Question 9. Which of the following best reflects the evidence on physiotherapy (physical therapy) as a treatment for spasticity in MS?

- There is good evidence that physiotherapy improves mobility and activities of daily living in people with progressive MS.
- There is good evidence that physiotherapy improves mobility and activities of daily living in people with relapsing, remitting MS.
- Although physiotherapy is a very common treatment for spasticity in MS, there is insufficient evidence from RCTs to be sure of its effectiveness.

Question 10. Which of the following interventions for MS is best supported by clinical trial evidence?

- Hyperbaric oxygen to slow the progress of the disease.
- Intravenous immunoglobulins to reduce the relapse rate and disease progression in relapsing, remitting disease.
- Amantadine to reduce the fatigue of MS.

Answer 1: Relapsing, remitting

In 90% of people, early disease is relapsing, remitting, characterized by episodes of neurological dysfunction interspersed with periods of stability. The other 10% have primary progressive disease, in which progressive neurological disability occurs from the outset. Most people with relapsing, remitting MS at presentation will go on to develop secondary progressive disease, usually about 6–10 years after onset [1].

In one study of the natural history of primary progressive MS (216 patients), the mean age of onset was 38.5 years, and the female:male ratio was 1.3:1 [2]. Relapsing, remitting MS typically begins in the second or third decade of life, and the female:male ratio is about 2:1 [3].

References

1. Boggild M, Ford H (2003) Multiple sclerosis. Clin Evid 2003: 1566–1581.
2. Cottrell DA, Kremenichtzky M, Rice GP, Koopman WJ, Hader W, et al. (1999) The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122: 625–639.
3. Noseworthy JH, Luchinetti C, Rodriguez M, Weinschenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938–952.

Answer 2: One in 800

The prevalence of MS in Europe and North America is one in 800 people, with an annual incidence of two to ten cases per 100,000 people, making MS the most common cause of neurological disability in young adults [1,2].

Regions with the highest prevalence of MS are Europe, Israel, Canada, northern United States, southeastern Australia, New Zealand, and easternmost Russia [3]. Medium frequency areas include southern United States, most of Australia, South Africa, the southern Mediterranean basin, Russia into Siberia, the Ukraine, and parts of Latin America. Prevalence rates under five per 100,000 are found in the rest of Asia, Africa, and northern South America.

References

1. Compston A (1997) Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 62: 553–561.
2. Boggild M, Ford H (2003) Multiple sclerosis. Clin Evid 2003: 1566–1581.
3. Kurtzke JF (2000) Multiple sclerosis in time and space—Geographic clues to cause. J Neurovirol 6(Suppl 2): S134–S140.

Answer 3: There is a gradient of increasing prevalence with increasing latitude

One of the most striking epidemiological features of MS is a gradient of increasing prevalence with increasing latitude [1]. For example, in Australia, the risk of developing MS in temperate Tasmania is 5-fold that in subtropical Queensland [2].

A recent case-control study found that higher levels of sun exposure during childhood and early adolescence, and greater actinic damage (skin damage from sun exposure), are associated with a reduced risk of MS; this association persisted after adjustment for fair skin and exposure after onset of disease [3]. These findings suggest that ultraviolet radiation may be beneficial against MS, possibly through increasing vitamin D levels [3].

References

1. Ebers GC, Sadovnick AD (1993) The geographic distribution of multiple sclerosis: A review. Neuroepidemiology 12: 1–5.
2. McLeod JG, Hammond SR, Hallpike JF (1994) Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 160: 117–122.
3. van der Me IAF, Ponsonby AL, Dover T, Blizzard L, Simmons R, et al. (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 327: 516.

Answer 4: Corticosteroids

One systematic review identified four randomized, controlled trials (RCTs) of methylprednisolone against placebo, and two of corticosteroids against placebo, in people with an acute exacerbation of MS (377 patients in total) [1]. Corticosteroids improved symptoms compared with placebo within the first five weeks of treatment.

One small, double-blind crossover RCT (22 people) provided insufficient evidence to assess the effects of plasma exchange in people with acute relapses of MS [2].

Interferon beta is used to prevent relapses and disability, not as a treatment for an acute relapse.

References

1. Filippini G, Brusaferri F, Sibley WA, Catterio A, Ciucci G, et al. (2004) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2004: CD001331.
2. Weinschenker BG, O’Brien PC, Peterson TM, Noseworthy JH, Luchinetti CF, et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878–886.

Answer 5: The optimal dose, duration of treatment, and route of administration are unclear

While a systematic review did show that corticosteroids are effective at reducing symptoms of an acute relapse [1], there was insufficient evidence from the trials to determine the optimal dose, duration, and route of administration [1,2].

A small subgroup analysis using an indirect comparison suggested no difference between five days and 15 days of treatment with methylprednisolone.

One of the RCTs included in the systematic review [1] found no significant difference between oral methylprednisolone and placebo in the prevention of new relapses after one year.

References

1. Filippini G, Brusaferri F, Sibley WA, Catterio A, Ciucci G, et al. (2004) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2004: CD001331.
2. Boggild M, Ford H (2003) Multiple sclerosis. Clin Evid 2003: 1566–1581.
**Answer 6: There is some evidence that interferon beta can reduce exacerbations and disease progression in people with relapsing, remitting disease**

One systematic review identified seven RCTs comparing interferon beta with placebo in people with active relapsing, remitting MS (two relapses in the previous two or three years) [1]. The review found that, over two years, interferon significantly reduced the risk of exacerbations and disease progression compared with placebo.

Two RCTs found that interferon beta given to patients after a first demyelinating event significantly reduced the risk of a second clinical event and, therefore, of conversion to a definitive diagnosis of MS [2,3].

Three RCTs provided insufficient evidence to assess the effects of interferon beta on disease progression in people with secondary progressive MS [4,5,6].

**References**

1. Rice GPA, Inocovia B, Munari L, Ebers G, Polman C, et al. (2004) Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2004: CD002092.
2. Jacobo LD, Beck RW, Simon H, Kinkel RP, et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 345: 898–904.
3. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 357: 1576–1582.
4. European Study Group on Interferon Beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491–1497.
5. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomised controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56: 1496–1504.
6. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59: 679–687.

**Answer 7: None of the above**

A systematic review of the RCTs of treatments for fatigue in MS found that exercise, behavior modification, and pemoline were all of “unknown effectiveness” [1].

**References**

1. Gray O, McDonnell GV, Forbes RB (2004) Intravenous immunoglobulins for the secondary prevention of relapses and disease progression in MS, two trials met the inclusion criteria (involving a total of 168 patients) [1]. These found a reduction in relapse rate and increased time to first relapse during treatment with intravenous immunoglobulins.

Another Cochrane systematic review included nine RCTs of hyperbaric oxygen versus a sham therapy in patients with MS [2]. Two trials produced generally positive results, but the remaining seven reported generally no evidence of a treatment effect. The reviewers concluded, “We found no consistent evidence to confirm a beneficial effect of hyperbaric oxygen therapy for the treatment of multiple sclerosis and do not believe routine use is justified.”

A third Cochrane systematic review included four RCTs of amantadine in patients with MS-related fatigue [3]. The reviewers concluded that the quality of the studies was poor and that all trials were open to bias. All of the studies reported small and inconsistent improvements in fatigue, but the clinical relevance of these findings and the impact on patients’ functioning and health-related quality of life remained uncertain. The reviewers concluded, “Amantadine treatment is generally well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented.”

**References**

1. Gray O, McDonnell GV, Forbes RB (2004) Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev 2004: CD002956.
2. Bennett M, Heard R (2004) Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004: CD00357.
3. Tapp C, Solari A, DiAmico R, Brančić P, Hyde C, et al. (2004) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2004: CD002818.

**Answer 8: A meta-analysis found a consistent association between stressful life events and subsequent exacerbations**

A recent meta-analysis, which included 14 individual studies, showed a significant increase in risk of exacerbation of MS after stressful life events [1]. Seven of the studies in the meta-analysis were prospective longitudinal studies.

**References**

1. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D (2004) Association between stressful life events and exacerbation in multiple sclerosis: A meta-analysis. BMJ 328: 731.

**Answer 9: Although physiotherapy is a very common treatment for spasticity in MS, there is insufficient evidence from RCTs to be sure of its effectiveness**

There have been two small RCTs, which provided insufficient evidence to assess the effects of physiotherapy in people with spasticity due to MS [1,2]. The first RCT (40 patients) found limited evidence that twice-weekly hospital- or home-based physiotherapy for eight weeks briefly improved mobility compared with no physiotherapy. The second RCT, involving 45 people with progressive MS, found no significant difference between early (week 5) and delayed (week 13) physiotherapy (two weeks of inpatient sessions) in mobility or activities of daily living.

**References**

1. Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran, et al. (2001) Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 70: 174–179.
2. Fuller KJ, Daeseon K, Wiles CM (1996) Physiotherapy in chronic multiple sclerosis: A controlled trial. Clin Rehabil 10: 195–204.

**Answer 10: Intravenous immunoglobulins to reduce the relapse rate and disease progression in relapsing, remitting disease**

In a Cochrane systematic review of RCTs of intravenous immunoglobulins for the secondary prevention of relapses and disease progression in MS, two trials met the inclusion criteria (involving a total of 108 patients) [1]. These found a reduction in relapse rate and increased time to first relapse during treatment with intravenous immunoglobulins.

Another Cochrane systematic review included nine RCTs of hyperbaric oxygen versus a sham therapy in patients with MS [2]. Two trials produced generally positive results, but the remaining seven reported generally no evidence of a treatment effect. The reviewers concluded, “We found no consistent evidence to confirm a beneficial effect of hyperbaric oxygen therapy for the treatment of multiple sclerosis and do not believe routine use is justified.”

A third Cochrane systematic review included four RCTs of amantadine in patients with MS-related fatigue [3]. The reviewers concluded that the quality of the studies was poor and that all trials were open to bias. All of the studies reported small and inconsistent improvements in fatigue, but the clinical relevance of these findings and the impact on patients’ functioning and health-related quality of life remained uncertain. The reviewers concluded, “Amantadine treatment is generally well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented.”

**References**

1. Bennett M, Heard R (2004) Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004: CD00357.
2. Bennett M, Heard R (2004) Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004: CD00357.
3. Tapp C, Solari A, DiAmico R, Brančić P, Hyde C, et al. (2004) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2004: CD002818.
Filippini G, Brusaferri F, Sibley WA, Gittero A, Ciucci G, et al. (2004) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2004: CD001331.

Fuller KJ, Dawson K, Wiles CM (1996) Physiotherapy in chronic multiple sclerosis: A controlled trial. Clin Rehabil 10: 195–204.

Gray O, McDonnell GV, Forbes RB (2004) Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev 2004: CD002936.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898–904.

Kurtzke JF (2000) Multiple sclerosis in time and space—Geographic clues to cause. J Neurovirol 6(Suppl 2): S134–S140.

McLeod JG, Hammond SR, Hallpike JF (1994) Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 160: 117–122.

Mohr DC, Hart SL, Julian L, Cox D, Pelletier D (2004) Association between stressful life events and exacerbation in multiple sclerosis: A meta-analysis. BMJ 328: 731.

Noseworthy JH, Luchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938–952.

Rice GPA, Incorvaia B, Munari L, Ebers G, Polman C, et al. (2004) Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2004: CD002802.

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomised controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56: 1496–1504.

Taus C, Solari A, D’Amico R, Branãs P, Hyde C, et al. (2004) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2004: CD002818.

van der Mei IAF, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, et al. (2005) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 327: 316.

Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran, et al. (2001) Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 70: 174–179.